Skip to main content
SpringerLink
Log in

Minimize exposure to antidopaminergic drugs whenever possible to reduce the risk of drug-induced parkinsonism and tardive dyskinesia

  • Drug Reactions and Interactions
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Drug-induced parkinsonism (DIP) and tardive dyskinesia (TD) are iatrogenic consequences of antidopaminergic drugs, and are most common in the elderly. To reduce the risk of DIP and TD, exposure to antidopaminergic drugs should be minimized, with the lowest effective dosage possible being used for the shortest treatment duration. Prevention and early detection of DIP and TD are essential, as evidence supporting the use of available treatment options is limited.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Estevez-Fraga C, Zeun P, López-Sendón Moreno JL. Current methods for the treatment and prevention of drug-induced parkinsonism and tardive dyskinesia in the elderly. Drugs Aging. 2018;35(11):959–71.

    Article  CAS  PubMed  Google Scholar 

  2. Fernandez HH, Trieschmann ME, Burke MA, et al. Quetiapine for psychosis in Parkinson’s disease versus dementia with Lewy bodies. J Clin Psychiatry. 2002;63(6):513–5.

    Article  CAS  PubMed  Google Scholar 

  3. Emsley R, Turner HJ, Schronen J, et al. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry. 2004;65(5):696–701.

    Article  CAS  PubMed  Google Scholar 

  4. Bassitt DP, Louza Neto MR. Clozapine efficacy in tardive dyskinesia in schizophrenic patients. Eur Arch Psychiatry Clin Neurosci. 1998;248(4):209–11.

    Article  CAS  PubMed  Google Scholar 

  5. Yaw TK, Fox SH, Lang AE. Clozapine in parkinsonian rest tremor: a review of outcomes, adverse reactions, and possible mechanisms of action. Mov Disord Clin Pract. 2016;3(2):116–24.

    Article  PubMed  Google Scholar 

  6. Savica R, Grossardt BR, Bower JH, et al. Incidence and time trends of drug-induced parkinsonism: a 30-year population-based study. Mov Disord. 2017;32(2):227–34.

    Article  PubMed  Google Scholar 

  7. Woerner MG, Alvir JM, Saltz BL, et al. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry. 1998;155(11):1521–8.

    Article  CAS  PubMed  Google Scholar 

  8. Sweet RA, Pollock BG, Rosen J, et al. Early detection of neuroleptic-induced parkinsonism in elderly patients with dementia. J Geriatr Psychiatry Neurol. 1994;7(4):251–3.

    Article  CAS  PubMed  Google Scholar 

  9. Tenback DE, van Harten PN, van Os J. Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis. Mov Disord. 2009;24(16):2309–15.

    Article  PubMed  Google Scholar 

  10. Shiroma PR, Geda YE, Mrazek DA. Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry. Pharmacogenomics. 2010;11(9):1305–30.

    Article  CAS  PubMed  Google Scholar 

  11. Metzer WS, Newton JE, Steele RW, et al. HLA antigens in drug-induced parkinsonism. Mov Disord. 1989;4(2):121–8.

    Article  CAS  PubMed  Google Scholar 

  12. Steen VM, Lovlie R, MacEwan T, et al. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry. 1997;2(2):139–45.

    Article  CAS  PubMed  Google Scholar 

  13. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry. 2008;13(5):544–56.

    Article  CAS  PubMed  Google Scholar 

  14. Erro R, Bhatia KP, Tinazzi M. Parkinsonism following neuroleptic exposure: a double-hit hypothesis? Mov Disord. 2015;30(6):780–5.

    Article  PubMed  Google Scholar 

  15. Foubert-Samier A, Helmer C, Perez F, et al. Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort. Neurology. 2012;79(15):1615–21.

    Article  CAS  PubMed  Google Scholar 

  16. Chung SJ, Yoo HS, Moon H, et al. Early-onset drug-induced parkinsonism after exposure to offenders implies nigrostriatal dopaminergic dysfunction. J Neurol Neurosurg Psychiatry. 2018;89(2):169–74.

    Article  PubMed  Google Scholar 

  17. Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs. 2003;17(1):47–62.

    Article  CAS  PubMed  Google Scholar 

  18. Elkashef AM, Wyatt RJ. Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E. Schizophr Bull. 1999;25(4):731–40.

    Article  CAS  PubMed  Google Scholar 

  19. Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord. 2012;27(10):1205–15.

    Article  PubMed  Google Scholar 

  20. Bordia T, Perez XA, Heiss J, et al. Optogenetic activation of striatal cholinergic interneurons regulates l-dopa-induced dyskinesias. Neurobiol Dis. 2016;91:47–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. López-Sendón Moreno JL, Alonso-Cánovas A, Buisán Catevilla J, et al. Substantia nigra echogenicity predicts response to drug withdrawal in suspected drug-induced parkinsonism. Mov Disord Clin Pract. 2016;3(3):268–74.

    Article  PubMed  Google Scholar 

  22. Lee PH, Kim JS, Shin DH, et al. Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry. 2006;77(3):372–4.

    Article  CAS  PubMed  Google Scholar 

  23. Cuberas-Borrós G, Lorenzo-Bosquet C, Aguadé-Bruix S, et al. Quantitative evaluation of striatal I-123-FP-CIT uptake in essential tremor and parkinsonism. Clin Nucl Med. 2011;36(11):991–6.

    Article  PubMed  Google Scholar 

  24. Lopez-Sendon JL, Mena MA, de Yebenes JG. Drug-induced parkinsonism in the elderly: incidence, management and prevention. Drugs Aging. 2012;29(2):105–18.

    Article  CAS  PubMed  Google Scholar 

  25. Friedman JH. Viewpoint: challenges in our understanding of neuroleptic induced parkinsonism. Parkinsonism Relat Disord. 2014;20(12):1325–8.

    Article  PubMed  Google Scholar 

  26. Wolf E, Seppi K, Katzenschlager R, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Mov Disord. 2010;25(10):1357–63.

    Article  PubMed  Google Scholar 

  27. Ory-Magne F, Corvol JC, Azulay JP, et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology. 2014;82(4):300–7.

    Article  CAS  PubMed  Google Scholar 

  28. Tinazzi M, Antonini A, Bovi T, et al. Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. J Neurol. 2009;256(6):910–5.

    Article  PubMed  Google Scholar 

  29. Moellentine C, Rummans T, Ahlskog JE, et al. Effectiveness of ECT in patients with parkinsonism. J Neuropsychiatry Clin Neurosci. 1998;10(2):187–93.

    Article  CAS  PubMed  Google Scholar 

  30. Berg JE. Electroconvulsive treatment of a patient with Parkinson’s disease and moderate depression. Ment Illn. 2011;3(1):e3.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother. 2006;6(1):7–17.

    Article  CAS  PubMed  Google Scholar 

  32. Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476–84.

    Article  PubMed  Google Scholar 

  33. Factor SA, Remington G, Comella CL, et al. The effects of valbenazine in participants with tardive dyskinesia: results of the 1-year KINECT 3 extension study. J Clin Psychiatry. 2017;78(9):1344–50.

    Article  PubMed  Google Scholar 

  34. Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88(21):2003–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013. https://doi.org/10.7916/D88P5Z71.

    Article  Google Scholar 

  36. Bergman H, Soares-Weiser K. Anticholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018;1:CD000204.

    PubMed  Google Scholar 

  37. Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2013;81(5):463–9.

    Article  PubMed  Google Scholar 

  38. Quik M, Zhang D, Perez XA, et al. Role for the nicotinic cholinergic system in movement disorders; therapeutic implications. Pharmacol Ther. 2014;144(1):50–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Ramirez-Castaneda J, Jankovic J. Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins (Basel). 2013;5(2):249–66.

    Article  CAS  Google Scholar 

  40. Spindler MA, Galifianakis NB, Wilkinson JR, et al. Globus pallidus interna deep brain stimulation for tardive dyskinesia: case report and review of the literature. Parkinsonism Relat Disord. 2013;19(2):141–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Ethics declarations

    Conflict of interest

    This article was adapted from Drugs & Aging 2018; 35(11):959–71 [1] by employees of Adis/Springer International, Ltd, who are responsible for the article content and declare no conflicts of interest.

    Funding

    The preparation of this review was not supported by any external funding.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Adis Medical Writers. Minimize exposure to antidopaminergic drugs whenever possible to reduce the risk of drug-induced parkinsonism and tardive dyskinesia. Drugs Ther Perspect 35, 326–331 (2019). https://doi.org/10.1007/s40267-019-00642-8

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-019-00642-8

    Search

    Navigation